☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC January Update

The Scottish Medicines Consortium has issued its monthly advice on new medicines.

Allergen extract of phleum pratense (Grazax®) has been rejected following a resubmission. Despite some modest clinical benefit the economic analysis was insufficiently robust to gain acceptance.

Beclometasone / formoterol metered dose inhaler (Fostair®) has been accepted for use in the treatment of asthma where a combination product is appropriate. This would be Step 3 of the British Thoracic Society Asthma Guidelines.

Latanoprost and timolol eye drops (Xalacom®) has been accepted for the treatment of raised intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.

Share 'SMC January Update' by emailShare 'SMC January Update' on FacebookShare 'SMC January Update' on TwitterShare 'SMC January Update' on LinkedInShare 'SMC January Update' on reddit


No Comments to “SMC January Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.